KURA
KURA
US50127T1097
Kura Oncology, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±62.5% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.47x
Defensive
Volatility (5Y p.a.)
62.5% p.a.
5-Year Horizon
Max Drawdown (5Y)
-76.5%
5-Year Horizon
Sharpe Ratio
-0.21
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +4.4%
3 Years 64.3% -76.5% 0.04 +5.1%
5 Years 62.5% -76.5% -0.21 -10.9%
10 Years 68.4% -86.7% 0.06 +6.3%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (62.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.7% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
7 ISS Score: 7 / 10
Audit Risk
5 ISS Score: 5 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
6.42
ende